AR027122A1 - COMPOSITION FOR THE TREATMENT OF DONATED FABRICS - Google Patents

COMPOSITION FOR THE TREATMENT OF DONATED FABRICS

Info

Publication number
AR027122A1
AR027122A1 ARP000106960A ARP000106960A AR027122A1 AR 027122 A1 AR027122 A1 AR 027122A1 AR P000106960 A ARP000106960 A AR P000106960A AR P000106960 A ARP000106960 A AR P000106960A AR 027122 A1 AR027122 A1 AR 027122A1
Authority
AR
Argentina
Prior art keywords
treatment
composition
donated
fabrics
wound
Prior art date
Application number
ARP000106960A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR027122A1 publication Critical patent/AR027122A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describe un agente farmacéutico para uso en el tratamiento (por ejemplo, curacion) de tejidos danados, tal como una herida, comprendiendo el agentefarmacéutico una composicion que comprende: (a) un factor de crecimiento; (b) un agente inhibidor; y , opcionalmente (c) un vehículo, diluyente o excipientefarmacéuticamente aceptable; pudiendo el agente inhibidor inhibir la accion de al menos una porteína adversa específica (por ejemplo, una proteasa específica)que está regulada positivamente en un entorno de tejido danado, tal como una herida.A pharmaceutical agent is described for use in the treatment (eg, healing) of damaged tissues, such as a wound, the pharmaceutical agent comprising a composition comprising: (a) a growth factor; (b) an inhibitory agent; and, optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; the inhibitory agent being able to inhibit the action of at least one specific adverse portein (for example, a specific protease) that is positively regulated in a damaged tissue environment, such as a wound.

ARP000106960A 1999-12-29 2000-12-27 COMPOSITION FOR THE TREATMENT OF DONATED FABRICS AR027122A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
AR027122A1 true AR027122A1 (en) 2003-03-12

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106960A AR027122A1 (en) 1999-12-29 2000-12-27 COMPOSITION FOR THE TREATMENT OF DONATED FABRICS

Country Status (12)

Country Link
EP (1) EP1242120A2 (en)
JP (1) JP2003519193A (en)
AR (1) AR027122A1 (en)
AU (1) AU1878201A (en)
CA (1) CA2395487A1 (en)
CO (1) CO5271671A1 (en)
EC (1) ECSP003859A (en)
GB (1) GB9930768D0 (en)
GT (1) GT200000224A (en)
PE (1) PE20011095A1 (en)
UY (1) UY26514A1 (en)
WO (1) WO2001049309A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE456655T1 (en) 2000-10-16 2010-02-15 Genentech Inc TREATMENT METHODS USING WISP POLYPEPTIDES
WO2003013569A2 (en) * 2001-07-27 2003-02-20 The Board Of Regents, The University Of Texas System Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
WO2005065706A1 (en) 2003-12-31 2005-07-21 Orthologic Corp. Pharmaceutical composition for thrombin peptide derivatives
JP5361386B2 (en) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Matrix metalloproteinase 11 vaccine
KR20150072458A (en) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
KR101629504B1 (en) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 Composition for improving skin conditions containing a combination of cytokines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (en) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd Novel composition for external use
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU1878201A (en) 2001-07-16
PE20011095A1 (en) 2001-10-27
UY26514A1 (en) 2001-07-31
GB9930768D0 (en) 2000-02-16
WO2001049309A3 (en) 2002-02-28
WO2001049309A2 (en) 2001-07-12
ECSP003859A (en) 2002-09-27
EP1242120A2 (en) 2002-09-25
CA2395487A1 (en) 2001-07-12
JP2003519193A (en) 2003-06-17
GT200000224A (en) 2002-06-15
CO5271671A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
BR0200782A (en) Compounds for the treatment of ischemia
CU23423B7 (en) OXAZOLIDINONES REPLACED AND ITS USE IN THE FIELD OF BLOOD COAGULATION
AR010385A1 (en) PROPIOPHENONE-DERIVED COMPOUND, PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE OF SUCH COMPOUND.
BR0207760A (en) Pharmaceutical composition, use thereof, methods for treating pain and inflammation, and process for preparing a composition
ES2159591T3 (en) COMPOSITION OF CONTROLLED RELEASE.
ES2065471T3 (en) ANTIBACTERIAL AQUEOUS COMPOSITIONS INCLUDING A SURFACTANT AND BACTERIOPHAGUS.
PA8468401A1 (en) COMPOUNDS FOR THE TREATMENT OF ISCHEMIA
AR030068A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAINFUL, INFLAMMATORY AND ULCEROUS CONDITIONS OF HUMED EPITELIAL SURFACES AS FOR EXAMPLE MUCOSITIS, STOMATITIS AND BEHCET SYNDROME
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
PE20010286A1 (en) INDOLOXOACETIL PIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS
PT750618E (en) OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
BR0014384A (en) Compounds for the treatment of ischemia
ATE218581T1 (en) CYCLOSPORINE DERIVATIVE, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION
BRPI0618374A2 (en) use of a pharmaceutically acceptable compound or derivative thereof, methods for killing clinically latent microorganisms in a mammal, for treating or preventing a microbial infection in a mammal, for sterilizing an object, for preserving an inorganic or organic material, for treating a disease , to reduce the dose of conventional antimicrobial agent required to treat a microbial infection and to treat a protozoan disease in a mammal, combined product, formulation, use of a combined product, compound, and process for preparing it.
BR0116084A (en) Arylated furanecarboxylic and thiophenecarboxylic acid amides with potassium channel blocking effect
AR007582A1 (en) COMPOSITION FOR WASHING THE SKIN, PROCEDURE FOR PREPARING IT AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, WHEN CASE, FOR COSMETIC TREATMENT OF THE SKIN.
AR027122A1 (en) COMPOSITION FOR THE TREATMENT OF DONATED FABRICS
DE69116380D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
MD20020075A (en) Antimicrobial preparation with retarded release of the biologically active component, utilization thereof and process for implant obtaining
ES2173923T3 (en) PROCEDURE THAT ALLOWS TO INACTIVATE A VIRUS IN THE PRESENCE OF A POLIETER AND AN AGENT.
ES2174921T3 (en) HIV PROTEASE INHIBITORS.
ECSP930933A (en) PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR PREPARING IT
AR022250A1 (en) PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.
ES2192779T3 (en) CRYSTALINE MODIFICATION OF 1- (2,6-DIFLUORBENCIL) -1H-1,2,3-TRIAZOL-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTICO.
DE69909747D1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING PEG-ASPARAGINASE, FOR THE TREATMENT OF HIV INFECTIONS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal